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Summary 
The acquisition of maternal  antibodies is critical for immunologic defense of the newborn.  In 
humans,  maternal  IgG is actively transported across the placenta.  The receptor responsible for 
this transport has not been identified definitively. We report the isolation from a placental cDNA 
library of clones encoding the oe-chain of an immunoglobulin G (IgG)-Fc receptor (hFcRn) that 
resembles a class I major histocompatibility complex antigen.  The DNA and predicted amino 
acid sequences are very similar to those of the neonatal rat  and mouse intestinal  Fc receptors, 
rFcRn and mFcP,  n. These receptors mediate transport of maternal IgG from milk to the blood- 
stream of the suckling rat or mouse. Like rat and mouse FcRn, hFcR_n binds IgG preferentially 
at low pH, which may imply that IgG binds hFcRn in an acidic intracellular compartment during 
transport  across the placenta. 
M 
ost materno-fetal IgG transport occurs after the 22nd 
. week of human pregnancy (1). During this time there 
are two cellular barriers in the placenta that IgG must cross: 
the syncytiotrophoblast and the fetal capillary endothelium. 
The microvillar surface of the syncytiotrophoblast is in con- 
tact with maternal blood.  In some regions of the placenta 
the syncytiotrophoblast is separated from the endothelium 
of the fetal vessels only by a basement membrane; elsewhere 
mesenchymal cells of the villous stroma and remaining cyto- 
trophoblast  intervene. 
The identity of the  receptors that  carry IgG  across  the 
human placenta is not known. Several IgG-binding proteins 
have been isolated from placenta (2, 3). FcyRII has been de- 
tected in placental endothelium  (4-7) and Fc3~RIII in syn- 
cytiotrophoblast (6, 7). Both of these receptors have relatively 
low affinities for monomeric IgG and function on leukocytes 
as receptors for immune complexes (8). Placental alkaline phos- 
phatase has  also been shown to bind  IgG (9). 
IgG has been observed in transport vesicles in neonatal rat 
intestinal epithelium (10). Rat FcP..n, which mediates intes- 
tinal IgG transport, consists of two subunits: fl2-microglob- 
ulin (fl2m)  and a large subunit  that  resembles MHC class 
I o~ chains (11). Late in gestation, a similar or identical FcR.n 
is present  in the fetal  yolk sac of rat  (12) and mouse (13). 
IgG has also been detected by immunoelectron  microscopy 
in vesicles in the human syncytiotrophoblast (14, 15) and en- 
dothelial cells (15).  These vesicles are presumed to mediate 
transcytosis of IgG in placenta. 
We  report  the  isolation  of cDNA  encoding  a  human 
homolog of the rat and mouse IgG transporting Fc receptor, 
FcRn. The presence of hFcRn RNA in the human placenta 
strongly suggests that this receptor functions in IgG trans- 
port in humans. 
Materials and Methods 
Cloning.  A human genomic DNA fragment containing  a se- 
quence similar to that encoding the a2 domain of rat FcRn was 
first cloned using a rFcRn cDNA probe (Mikulska, J. E. and N. E. 
Simister, unpublished results). A ~gt11 cDNA library of human 
full term placenta (Clontech,  Palo Alto, CA) was probed at high 
stringency (final wash 60~  0.1x  SSC, 0.1% SDS) with a frag- 
ment  of human  genomic  DNA encoding  the c~2 domain  of a 
homolog of rat  and mouse FcR.n. 
Sequence Determination and Analysis.  DNA sequencing was done 
by thermal cycle sequencing using the Circumvent TM Kit (New En- 
gland Biolabs, Beverly, MA). Contig assembly was done using a 
prerelease version of SeqApp by Don Gilbert (Indiana University, 
Bloomington,  IN). Multiple  sequence alignment  was done on a 
DEC VAX using  the GCG package (16). 
Expression and Binding Assay.  hFcRn clone #3 was subcloned 
into  the pREP9 eukaryotic expression vector (Neor; Invitrogen, 
San Diego, CA). 5 #g DNA was transfected into one 10 cm plate 
of 293 cells using a CaPO4 method (17). Cells were diluted and 
placed under G418 selection. Individual G418-resistant colonies  were 
expanded for binding  assays. The presence of hFcRn transcripts 
in these lines was confirmed by Northern blots (data not shown). 
Fc and IgG were purchased from Jackson Immunoresearch (West 
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Figure  1.  The complete nucleotide  and deduced amino acid sequence of hFcRn c~ chain.  The potential  ATG start is marked over the initiation site 
consensus nucleotides (27).  The most probable NH2-terminus  after signal peptide cleavage (28) is indicated by + 1. A potential site of Ash-linked glycosy- 
lation (Asn-X-Ser),  the predicted hydrophobic membrane-spanning  segment and polyadenylation  signals are underlined.  These polyadenylation  signals 
have each been reported to be "~10% as efficient as the canonical AATAAA signal in polyadenylation  assays in vitro (29). These sequence data are available 
from EMBL/GenBank/DDBJ  under accession  number U12255. 
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Figure  2.  Domain  by  domain 
comparison of the predicted amino 
acid sequence of hFcRa with rFcKn 
and mFcP,  n. Identities are indicated 
by a vertical bar. Labeled bars over 
the sequence indicate  ordered sec- 
ondary structure elements assigned 
based  on  the  crystal  structure  of 
rFcP,  m (30).  The sequence data for 
hFcRn are available from EMBL/ 
GenBank/DDBJ  under  accession 
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Transfected  Control 
Figure 3.  Fc binding by human FcP,  n. Binding of 12Sl-Fc  by 293 cells 
stably transfected with hFcRn ~x-chain cDNA in the expression vector 
pREP9 (Invitrogen) or untransfected.  Assays  were done at 37  ~ with (filled 
columns) and without (open  columns) competing unlabeled IgG, at pH 6.0 
and 7.5. Each column represents the mean cell-associated  radioactivity  of 
three wells; bars indicate the SE. 
Grove,  PA). Fc fragment of human IgG was labeled  with Na12SI 
to a specific activity of "o0.5 Ci/#mol  using Iodogen  |  (Pierce, 
Rockford, IL). 
Cells  expressing the hFcKn and nontransfected controls were 
seeded into  12-well plates  at  10  s cells/weU  and assayed 2 d later 
when they had reached near confluence. The cells were first washed 
with  DMEM,  pH  6.0  or  7.5.  Then,  mI-Fc (200  ng/ml,  4  ￿ 
10 -9 M) in DMEM, 1 mM KI, 1% fish gelatin (Sigma Chemical 
Co., St. Louis, MO), 20 mM Hepes, pH 6.0 or 7.5 with or without 
0.5 mg/ml unlabeled human IgG (3.3  x  10-6  M) was added. The 
ceils were allowed  to bind and take up IgG/Fc for 2 h  at 37~ 
Cells were then cooled to 4~  and unbound ligand was removed 
with three washes of chilled PBS, 1 mM KI, pH 6.0 or 7.5. Cells 
were dissolved  in 0.1  N  NaOH  and transferred to vials. Bound 
radioligand was measured in a gamma counter (CliniGamma model 
1272; LKB Wallac,  Piscataway,  NJ). 
Northern  Blots.  A  human multiple tissue  Northern blot was 
purchased from Clontech. For a second blot, total cellular  RNA 
from human tissues (10 #g/lane) was run on a denaturing agarose 
gel and transferred to a nylon membrane (Biotrans~; ICN, Irvine, 
CA). RNA was cross-linked to the membrane by UV illumination 
(Stratalinker|  Stratagene, La JoUa, CA). Both blots were hybrid- 
ized with 2  x  106 cpm/ml of 32p-labeled probe made by a random 
primer method (Prime-it  |  RmT, Stratagene) and passed through 
a 1-ml G25 spin column to remove free nucleotides. The blot was 
hybridized for 1 h in Quickhyb  |  (Stratagene) at 68~  the final 
wash was 0.1x  SSC, 0.1% SDS at 60~  The blot was exposed 
on a phosphor screen  (Kodak, Rochester, NY) and analyzed on 
a phosphorimager (Molecular Dynamics, Sunnyvale,  CA). 
Results  and  Discussion 
A human genomic DNA fragment containing a sequence 
similar to that encoding the or2 domain of rat FcR.n was first 
cloned using  a  rFcR.n cDNA  probe.  We used  this  human 
DNA  to probe a human placental cDNA  library,  and iso- 
lated five independent cDNA clones. Three of these contained 
an identical 1,098-nucleotide open reading frame (ORE Fig. 
1);  two  lacked the  first  351  bases  of the  ORE  The OKF 
was followed by 212 bp of Y-untranslated sequence including 
two potential polyadenylation signals: AATATA at  -17 and 
AATACA  at  -47  nucleotides upstream  of a  poly(A)  tail. 
The human cDNA sequence and its deduced amino acid 
sequence were very similar to those of the rFcKn cz chain, 
with  69%  nucleotide  identity  over  the  ORF,  and  65% 
predicted amino acid identity (Fig. 2). The amino acid iden- 
tity between the rat and human homologs was 65%  in the 
eel domain, 64% in cz2, 73% in or3, 63% in the transmem- 
brahe region, and 55% in the cytoplasmic tail.  Only one of 
the four potential sites for N-linked glycosylation shared by 
rat and mouse FcRn was present in the human protein,  at 
Asn 102. Notably absent was the site in or1, Ash 87 in rFcKn, 
that is almost ubiquitous in class I MHC proteins. The loop 
in which this site would lie was two residues shorter in human 
FcRn than in the rat and mouse receptors.  One of the two 
aromatic residues  in  the cytoplasmic region  of rFcRn  and 
mFcRn was present in the human protein (Trp 309).  A  di- 
leucine motif (positions  320  and  321)  was  also  conserved. 
Both of these elements are potential signals for endocytosis (18). 
Figure 4.  Northern  blots of RNA from human 
tissues. (a) Human  multiple tissue Northern  blot 
(Clontech) hybridized with a 120-bp probe from the 
3' untranslated sequence of hFcRn (top) and with a 
fl-actin control probe (bottom). Tissues  are heart (H), 
brain (/3), placenta (P), lung (Lu), liver (Li), skeletal 
muscle  (M), kidney  (K) and pancreas  (Pa). (b) Northern 
blot of human KNA hybridized  with a 120-bp probe 
from the 3' untranslated sequence  of hFcKn. Tissues 
are fetal kidney  (FK), fetal spleen  (F$), fetal intestine 
(1=1), adult intestine (AI),  and placenta (P). Loading 
of  lanes was approximately  equal, as  judged by ethidium 
bromide staining of ribosomal KNAs (not shown). 
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receptor, we transfected one of the cDNAs into the human 
293 cell line and measured the binding of radiolabeled human 
Fc. Cells that expressed hFcRn bound Fc specifically  at pH 
6.0 but not at pH 7.5; untransfected cells showed no specific 
binding at either pH (Fig. 3). The same pH dependence of 
binding has been observed for rFcRn (19). The optimum pH 
for IgG binding to placental membranes has also been reported 
to be between 5 and 6.5 (20, 21). The pHs of maternal and 
fetal blood are close to neutral (22) and that of stroma is ex- 
pected to be similar,  so hFcRn could not bind IgG at the 
surface of the syncytiotrophoblast or endothelium. A similar 
situation exists in the rat fetal yolk sac endoderm, where FcRn 
appears to transport IgG without a pH gradient (12). In this 
tissue,  FcRn is detected not at the apical plasma membrane 
but in apical  vesicles.  It  has  been suggested that  these are 
acidified  endocytic vesicles where IgG that was taken up by 
fluid-phase endocytosis binds FcRn (12).  A  similar mecha- 
nism has been proposed for placental IgG transport (15). The 
ability of hFcRn to bind IgG at acidic but not neutral pH 
would enable this receptor to transport  IgG by binding  it 
in endosomes of syncytiotrophoblast or in the endothelium 
of placental vessels and releasing it into the stroma or fetal 
blood. 
Finally,  we examined the tissue distribution of hFcRn a 
chain mRNA using Northern blots. A 1.5-kb transcript was 
present in RNA from full-term  human  placenta,  and also 
heart,  lung,  liver,  muscle, kidney,  pancreas,  and both fetal 
and adult small intestine (Fig.  4). The signal did not repre- 
sent crosshybridization with class I MHC mRNA because 
it was detected with a probe from the 3' untranslated region 
of hFcRn which is unlike the class I sequences.  The mRNA 
detected in fetal intestine is likely to encode the receptor respon- 
sible for the pH-dependent IgG binding activity in this tissue 
(23).  Placental  endothelial cells make ~2m (24).  Syncytiotro- 
phoblast lacks classical class I MHC proteins and was reported 
to contain no fl2m (24), but recent reevaluation  suggests that 
B2m  is  present,  although  nonuniformly  distributed  (J. S. 
Hunt, personal communication). Thus, functional FcRn could 
be assembled in endothelial cells or in/32m-positive regions 
of syncytiotrophoblast. 
The expression in human placenta of a homolog of the 
rodent IgG-transporting Fc receptor strongly implicates hFcRn 
in IgG transport  across  the placental barrier.  Future iden- 
tification of the placental cell types in which hFcRn is ex- 
pressed, by in situ hybridization or immunohistochemistry, 
will be necessary to clarify its role. The clinical  importance 
of maternal IgG for the immunologic defense of the neonate 
is well established.  Not all antibodies are beneficial,  how- 
ever. Maternal IgG antibodies resulting from isoimmuniza- 
tion by fetal  erythrocytes, leukocytes, or platelets (25) and 
autoantibodies in SLE and other autoimmune diseases of the 
mother  (26)  may harm  the fetus.  Identification  of the  Fc 
receptor that transports maternal IgG to the fetus would be 
a first step toward rational intervention in pregnancies com- 
plicated by these conditions. 
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